Lead Product(s): PF614
Therapeutic Area: Psychiatry/Psychology Product Name: PF614-MPAR
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: NATIONAL INSTITUTE DRUG ABUSE
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Funding July 08, 2021
PF614-MPAR™ is designed as an extended-release oxycodone prodrug with both trypsin-activated abuse protection (TAAP) and overdose protection through multi-pill abuse resistance (MPAR™) technology.